Genomics plc Appoints Sekar Kathiresan as Scientific Advisory Board Chair
News Jan 11, 2016
Dr Kathiresan is one of the world leaders in the genetics of heart disease. He is the director of preventive cardiology at Massachusetts General Hospital, an associate member in the Broad Institute’s Program in Medical and Population Genetics, and an associate professor of medicine at Harvard Medical School. He received his B.A. in history and graduated summa cum laude from the University of Pennsylvania in 1992. He received his M.D. from Harvard Medical School in 1997. Sekar completed his clinical training in internal medicine and cardiology at MGH and served as Chief Resident in Internal Medicine at MGH in 2002-2003. He pursued research training in cardiovascular genetics through a combined experience at the Framingham Heart Study and the Broad Institute of MIT and Harvard. In 2008, he joined the research faculties of the MGH Cardiovascular Research Center and the MGH Center for Human Genetic Research. In 2015 Sekar was selected by the National Institutes of Health to join a panel of experts formed to steer President Obama's Precision Medicine Initiative.
Sekar Kathiresan, M.D., said: “Genomics plc is dedicated, as am I, to making sense of the explosion in genomic data to improve patient care. The Company has developed a unique analytical platform for genomic data analysis and interpretation, and I am excited to be joining the Genomics SAB. I look forward to working with the team to help guide the next stage in the Company’s development.”
John Colenutt, CEO at Genomics plc, said: “I would like to welcome Sek to Genomics plc. We have established the SAB to support the Company in achieving its ambitions as a leading analysis company in the genomics space. We are delighted to be working with such a highly-regarded and world-renowned human geneticist. I am confident that Sek’s experience and knowledge will prove a tremendous asset as Genomics plc gains momentum and continues to grow – his appointment as Chair demonstrates our commitment to being a global leader in the field of genomics.”